Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature.

Autor:	Chiang CL; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Guo Q; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China., Ng WT; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Lin S; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China., Ma TSW; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Xu Z; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Xiao Y; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China., Li J; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Lu T; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China., Choi HCW; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Chen W; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Chau ESC; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Luk PHY; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Huang SH; Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., O'Sullivan B; Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., Pan J; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China., Lee AWM; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Sep 02; Vol. 11, pp. 703995. Date of Electronic Publication: 2021 Sep 02 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.703995
Abstrakt:	This study aims to identify prognostic factors in nasopharyngeal carcinoma (NPC) to improve the current 8th edition TNM classification. A systematic review of the literature reported between 2013 and 2019 in PubMed, Embase, and Scopus was conducted. Studies were included if (1) original clinical studies, (2) ≥50 NPC patients, and (3) analyses on the association between prognostic factors and overall survival. The data elements of eligible studies were abstracted and analyzed. A level of evidence was synthesized for each suggested change to the TNM staging and prognostic factors. Of 5,595 studies screened, 108 studies (44 studies on anatomical criteria and 64 on non-anatomical factors) were selected. Proposed changes/factors with strong evidence included the upstaging paranasal sinus to T4, defining parotid lymph node as N3, upstaging N-category based on presence of lymph node necrosis, as well as the incorporation of non-TNM factors including EBV-DNA level, primary gross tumor volume (GTV), nodal GTV, neutrophil-lymphocyte ratio, lactate dehydrogenase, C-reactive protein/albumin ratio, platelet count, SUVmax of the primary tumor, and total lesion glycolysis. This systematic review provides a useful summary of suggestions and prognostic factors that potentially improve the current staging system. Further validation studies are warranted to confirm their significance. Competing Interests: CC: Consulting or Advisory Role: AstraZeneca, Eiasi; Research funding: AstraZeneca, Merck Kgga. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Chiang, Guo, Ng, Lin, Ma, Xu, Xiao, Li, Lu, Choi, Chen, Chau, Luk, Huang, O’Sullivan, Pan and Lee.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu